The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.

Leukemia · 2013 · PMC3567236 · PMID 22810506

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

of borderline significanceP =0.05actually significant

For PFS, the LC 90 for fludarabine added independent prognostic value ( P =0.002), though the LC 90 for chlorambucil was of borderline significance ( P =0.05) and for mafosfamide was nonsignificant.

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.